Varicella in pediatric patients.
OBJECTIVE
To summarize the literature describing the epidemiology, transmission, clinical manifestations, diagnosis, treatment, and prevention of varicella in the pediatric population.


METHODS
A literature search of English-language articles from 1982 to 1992 using MEDLINE and bibliographies of relevant articles. The search term used was varicella.


METHODS
All review articles and original studies addressing the epidemiology, transmission, clinical manifestations, complications, diagnosis, treatment, and prevention of varicella in pediatric patients were reviewed. Emphasis was placed on controlled studies done in the US.


METHODS
Data from human studies were extracted by the authors and evaluated according to patient population, sample size, dosing regimen, efficacy, and safety.


RESULTS
Varicella-zoster virus is a highly contagious virus that produces a common and costly disease in the pediatric population. The primary manifestation of varicella is the eruption of vesicular lesions. In most cases varicella is benign, but it can be associated with serious complications. Diagnosis is based primarily on clinical findings. Otherwise healthy children have traditionally received only symptomatic treatment for varicella, but recent literature suggests that antiviral therapy may be useful in these patients. Immunocompromised patients benefit from both symptomatic and antiviral therapy. Isolation and varicella-zoster immune globulin are used to prevent varicella. In the future, varicella vaccine will play an important role in preventing the disease. Varicella vaccine has been shown to be immunogenic and clinically effective in both healthy and immunocompromised children. Adverse reactions associated with the vaccine include fever, injection-site reactions, and rash. Although zoster can follow vaccination, the incidence appears to be lower in vaccinated individuals. Preliminary studies have shown that the vaccine provides protection from varicella-zoster virus for an extended period of time.


CONCLUSIONS
Varicella is a common, usually benign disease of childhood. All patients may benefit from symptomatic therapy. Current literature does not support the use of antiviral therapy in all pediatric patients with varicella. When commercially available, varicella vaccine will play an important role in prevention. Long-term studies are needed to fully assess the risk of developing varicella and zoster following vaccination.
Department of Pharmacy Practice and Administration, Massachusetts College of Pharmacy and Allied Health Sciences, Boston 02115.
L A
LA
Drwal-Klein
C A
CA
O'Donovan
D000212:Acyclovir / Q000627:therapeutic use; D000293:Adolescent; D000998:Antiviral Agents / Q000627:therapeutic use; D002644:Chickenpox / Q000150:complications / Q000276:immunology / Q000517:prevention & control; D019433:Chickenpox Vaccine; D002648:Child; D002675:Child, Preschool; D014645:Herpesvirus 3, Human / Q000276:immunology; D006801:Humans; D016867:Immunocompromised Host; D016756:Immunoglobulins, Intravenous / Q000627:therapeutic use; D007223:Infant; D007231:Infant, Newborn; D014613:Vaccines, Attenuated; D014765:Viral Vaccines
D000998:Antiviral Agents; D019433:Chickenpox Vaccine; D016756:Immunoglobulins, Intravenous; D014613:Vaccines, Attenuated; D014765:Viral Vaccines; D000212:Acyclovir